PDIA3 and Alzheimer disease: Alterations in Pdia3 levels also appeared to be age- and/or pathology-dependent, corroborating the ER chaperone’s involvement in AD pathology, and supporting the Pdia3 protein as a potential novel therapeutic target for the treatment of AD [71].